|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 401/04 | (2006.01) |
| (11) | Number of the document | 2882737 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13753455.8 |
| Date of filing the European patent application | 2013-08-08 | |
| (97) | Date of publication of the European application | 2015-06-17 |
| (45) | Date of publication and mention of the grant of the patent | 2019-02-20 |
| (46) | Date of publication of the claims translation | 2019-04-25 |
| (86) | Number | PCT/US2013/054064 |
| Date | 2013-08-08 |
| (87) | Number | WO 2014/025964 |
| Date | 2014-02-13 |
| (30) | Number | Date | Country code |
| 201261681484 P | 2012-08-09 | US |
| (72) |
COHEN, Benjamin, M., US
TRAVERSE, John, F., US
XU, Jean, US
LI, Ying, US
|
| (73) |
Celgene Corporation,
86 Morris Avenue, Summit, NJ 07901,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | (S)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diono hidrochlorido kieta forma |
| A SOLID FORM OF (S)-3-(4-((4-MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE HYDROCHLORIDE |
| Payment date | Validity (years) | Amount | |
| 2025-07-03 | 13 | 289.00 EUR |
| 2026-08-08 |